Skip to main content
GIPResearch.com · Patent and Technology Research

GE HEALTHCARE LIMITED GRANTED PATENT FOR ENANTIOMERIC SEPARATION AND PURIFICATION OF 2 ,3 ,4 ,9 -TETRAHYDRO- 1H -CARBAZOLE -4 -CARBOXYLIC ACID AMIDE DERIVATIVES.

GE Healthcare Limited produces, generates, and markets medical goods.

Save or follow this source
These actions open third-party AI services. Saving, citation, and future recall are not guaranteed.
Conceptual GIPResearch illustration for GE HEALTHCARE LIMITED GRANTED PATENT FOR ENANTIOMERIC SEPARATION AND PURIFICATION OF 2 ,3 ,4 ,9 -TET
Research and original publication material

GE HEALTHCARE LIMITED GRANTED PATENT FOR ENANTIOMERIC SEPARATION AND PURIFICATION OF 2 ,3 ,4 ,9 -TETRAHYDRO- 1H -CARBAZOLE -4 -CARBOXYLIC ACID AMIDE DERIVATIVES. — research background

Research context: This article preserves existing publication material for continuity. Technical, commercial and legal references should be checked against current primary sources before making decisions.

GE Healthcare Limited produces, generates, and markets medical goods. The Company operates two divisions, the imaging division specializes in x-rays, nuclear imaging, MRI's, ultrasound, and radiotherapy, and the life science division focuses on drug discovery systems, research and laboratory instruments, and systems for biopharmaceutical manufacturing and purification. In India, the business of GE Healthcare Limited focuses on the alkylation method, crystallization process of tricyclic indole derivatives, non-invasive method for pressure measurement, radiotracer compositions and methods, radiolabelling method, and radiolabelled octreotide analogs as pet tracers. GE Healthcare Limited filed a patent application numbered 10100/DELNP/2015 that is titled ENANTIOMERIC SEPARATION AND PURIFICATION OF 2, 3, 4, 9 -TETRAHYDRO- 1H -CARBAZOLE -4 -CARBOXYLIC ACID AMIDE DERIVATIVES. The patent has been filed in the field of Chemicals. This Patent Application has been granted as Patent Number 352336. This invention relates to a method comprising, separating an S-enantiomer from an R-enantiomer wherein said S-enantiomer and said R-enantiomer is provided in a racemic mixture and wherein each of said S-enantiomer and said R-enantiomer is a compound of wherein R1 is C1-4 alkylene-LG wherein LG is a leaving group. During the patent examination, the Patent Examiner raised objections under Section 3(d) of the Patents Act, 1970 stating that the subject matter of the claims relate to a mere derivative of known process and known compound of prior art and also fail to describe any significant improvement with respect to the therapeutic effect. As a response, the Applicant submitted that the method is novel and inventive over the cited prior arts since none of the cited prior art suggests addition of water to perform the precipitation step, thereby to successfully obtain good quality powder form of the compounds of present Formula I. Further, certain claims have been deleted to render the objection moot. Advocate Rahul Dev is a Patent Attorney & International Business Lawyer practicing Technology, Intellectual Property & Corporate Laws. He is reachable at rd (at) patentbusinesslawyer (dot) com & @rdpatentlawyer on Twitter. Quoted in and contributed to 50+ national & international publications (Bloomberg, FirstPost, SwissInfo, Outlook Money, Yahoo News, Times of India, Economic Times, Business Standard, Quartz, Global Legal Post, International Bar Association, LawAsia, BioSpectrum Asia, Digital News Asia, e27, Leaders Speak, Entrepreneur India, VCCircle, AutoTech). Regularly invited to speak at international & national platforms (conferences, TV channels, seminars, corporate trainings, government workshops) on technology, patents, business strategy, legal developments, leadership & management.

Discuss a research question related to GE HEALTHCARE LIMITED GRANTED PATENT FOR ENANTIOMERIC

Describe your objective and the evidence you need. The suitability and scope of any research engagement will be confirmed individually.

Discuss a research question

Source and context: Original GIPResearch.com publication dated 2020-12-10. Existing text is retained for historical continuity. Verify time-sensitive matters using official records.

None

Featured Work & Insights